What is Zacks Research’s Estimate for Pfizer Q4 Earnings?

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of Pfizer in a report released on Monday, November 18th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $0.39 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.80 EPS.

Other equities research analysts have also recently issued reports about the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Stock Up 2.0 %

NYSE PFE opened at $25.63 on Thursday. The business’s fifty day simple moving average is $28.21 and its 200-day simple moving average is $28.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $145.24 billion, a PE ratio of 34.64, a P/E/G ratio of 0.80 and a beta of 0.67. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) earnings per share.

Institutional Trading of Pfizer

A number of large investors have recently modified their holdings of the stock. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Gladius Capital Management LP grew its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP purchased a new stake in shares of Pfizer during the second quarter worth approximately $31,000. Finally, Financial Connections Group Inc. acquired a new stake in Pfizer in the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.